Sept 7 (Reuters) - U.S.-based Valeant Pharmaceuticals International (VRX.N), which agreed to be bought by Canada’s Biovail Corp (BVF.TO) in June, said they would cut about 25 percent of the combined company’s U.S. and Canadian workforce as part of the integration plans.
